TAVR Transaortic Approach: New Trends in Aortic Valve Surgery
|
|
- Polly Hensley
- 5 years ago
- Views:
Transcription
1 : New Trends in Aortic Valve Surgery Marc R. Moon, M.D. John M. Shoenberg Chair in CV Disease Chief, Cardiac Surgery Director, Center for Diseases of the Thoracic Aorta Washington University School of Medicine St. Louis, MO USA AATS Cardiovascular Valve Symposium São Paulo, Brazil, Saturday November 21, 2015 Disclosures: NONE
2 MULTIPLE ACCESS OPTIONS Transfemoral Approach Transapical Approach Transaortic Approach
3 Annual TAVR Volume TF vs. ALTERNATIVE ACCESS Wash U (projected) Transfemoral Alternative Access
4 POOR TRANSAPICAL CANDIDATE Severe COPD No previous sternotomy Bleeding Ventricular dysfunction Less pulmonary dysfunction Immunocompromised Significantly EF
5 Myocardial Injury after TAVR LV apex injury Transapical Barbash et al.
6 POTENTIAL ADVANTAGES Mini-sternotomy incision Avoids TAVR-TA risks Bleeding Ventricular dysfunction Less pulmonary dysfunction Preserves the advantages of TA Ease of positioning Avoidance of arch manipulation Can be safely performed in most patients including prior sternotomy
7 TA vs. TAo Wash U.
8 SURGICAL TECHNIQUE Wash U. Ferrari et al.
9 SURGICAL TECHNIQUE Wash U.
10 SURGICAL TECHNIQUE Wash U. TAo Zone Straight shot into the valve Free of calcium ~ 6 cm from the valve
11 SURGICAL TECHNIQUE Wash U. Porcelain Aorta? Use CT to identify Ca ++ -free Zone
12 SURGICAL TECHNIQUE Wash U. TAo Zone Sapien (23-29mm): 5-6 cm CoreValve (all sizes): >6 cm
13 SURGICAL TECHNIQUE Wash U.
14 Mini-Sternotomy vs. Right Thoracotomy Assess relationship between aorta, sternum, and rib cage at the level of the 2 nd rib Distance from rib to aorta % of aorta to the right of the sternum Thoracotomy ok if <6cm and >50% aorta is to the right Vinnie Bapat - London AATS 2013: Minneapolis
15 Mini-Sternotomy vs. Right Thoracotomy Aorta <5cm from sternum but left Aorta on right but > 7 cm deep
16 Mini-Sternotomy vs. Right Thoracotomy Aorta <5cm from sternum but left Aorta on right but > 7 cm deep With a rightward J mini-sternotomy, you can access almost all aortas
17 PREOP CT PLANNING Wash U. Mini-sternotomy in redo Vein & Ao not close to sternum LIMA is lateral, RIMA Ø cross midline
18 SURGICAL TECHNIQUE Wash U. Mini-sternotomy in redo Vein & Ao not close to sternum LIMA is lateral, RIMA Ø cross midline
19 SURGICAL TECHNIQUE Wash U.
20 Transapical vs. Transaortic Outcomes of inoperable pts undergoing transapical and transaortic TAVR Baseline TA Patients (N = 125) TAo Patients (N = 94) p-value Aortic Valve Area cm ± ± Aortic Valve Area Index 0.39 ± ± Mean gradient mm Hg ± ± LV Ejection Fraction % ± ± Days Aortic Valve Area cm ± ± Aortic Valve Area Index 0.93 ± ± Mean gradient mm Hg 8.36 ± ± 3.91 <0.001 LV Ejection Fraction % ± ± PARTNER 2 Substudy ACC 2014: Wash., DC
21 Myocardial Injury after TAVR Transaortic vs. Transapical All pts: Baseline vs mo F/U (45 Tao, 206 TA) Propensity matched (102 pts) Ribiero et al, The Annals of Thoracic Surgery, Volume 99, Issue 6, 2015,
22 Real World Data TVT Registry TA 4,085 pts, TAo 868 pts ( ) Conclusion: Patients undergoing TAo were older, more likely female, with higher STS scores than patients with TA access. There were no risk-adjusted differences between TA and TAo access in mortality, stroke, or readmission rates up to 1 year. p = ATS 2015:100:1718
23 CoreValve Pivotal Trial Alternative access, 150 patients (CoreValve US Pivotal) Extreme high-risk AS with prohibitive iliofemoral anatomy Direct aortic approach (n = 80) Proceudre time 55 ± 40 min PRBCs in 35% Subclavian artery approach (n = 70) Proceudre time 67 ± 53 min PRBCs in 11% AATS 2014: Toronto JTCVS 2014: 148:2869
24 TAVR Alternative Access SURGICAL RESULTS Wash U. Baseline Variable TA (n=87) TAo (n=36) P Variable TA (n=128) TAo (n=113) P BASELINE Age (mean, years) 79 ± 8 79 ± Female gender 29 (33%) 13 (36%) 0.84 Female gender 51 (40%) 67 (59%) STS preoperative risk of mortality 11.1 ± ± Peripheral vascular disease 71 (82%) 29 (81%) 1.00 Age (years) 80.0 ± ± Cerebrovascular disease 33 (38%) 15 (42%) 0.84 Left ventricular ejection fraction (%) 50 ± ± STS risk score, % * 10.9 ± ± Chronic obstructive pulmonary disease 53 (61%) 24 (67%) 0.68 Diabetes 57 (46%) 54 (48%) Diabetes Mellitus 40 (46%) 20 (56%) 0.43 Body mass index 27 ± 6 30 ± Creatinine 1.25 ± ± Renal failure 9 (10%) 5 (14%) Peri-and Post-operative Renal failure 13 (10%) 13 (12%) Intraoperative PRBC use 38 (44%) 8 (22%) 0.04 Surgery time (hours) 2.27 ± ± HTN 118 (92%) 110 (97%) Extubated in OR 68 (78%) 33 (92%) 0.12 Dyslipidemia 120 (94%) 103 (91%) Prolonged ventilation (> 24hours) 7 (8%) 1 (3%) 0.44 Cerebrovascular Accidents 2 (2%) 1 (3%) 1.00 Immunocompromise 11 (9%) 20 (18%) Length of Stay (days) 6.9 ± ± Operative mortality 7 (8%) 1 (3%) 0.44 PVD 98 (77%) 87 (77%) CVD 51 (40%) 40 (35%) 0.507
25 SURGICAL RESULTS Wash U. VARIABLE BASELINE TF (n=179) Alt. Access (n=221) Female gender 83 (47%) 112 (51%) Age (mean, years) 81.7 ± ± STS risk score (%) 9.1 ± ± Peripheral vascular disease 51 (29%) 172 (7%) <0.001 Cerebrovascular disease 39 (22%) 76 (34%) INTRAOPERATIVE Procedure time (hours) 2.3 ± ± Fluoroscopy time (minutes) 21.4 ± ± 7.2 <0.001 Contrast dose (ml) 84.7 ± ± 29.8 <0.001 Any blood product 34 (19%) 104 (47%) <0.001 Extubated in OR 161 (89%) 188 (85%) POST-OPERATIVE Length of stay (mean, days) 5.7 ± ± 5.8 <0.001 Cerebrovascular accident 2 (1%) 4 (2%) day mortality 4 (2%) 15 (7%) year mortality 21 (16%) 16 (10%) P STSA 2015, Orlando, FL
26 IMPACT ON PROVIDER
27 IMPACT ON PROVIDER Radiation exposure: Operator position Imaging equipment specs Amount/location of shielding Study at Wash U. Dosimeters during TAVR (n=81) : TF vs. alternate access Cath lab vs. hybrid OR Disposable radiation shielding pads (randomized) Wash U. Submitted to AATS 2016
28 mrad/min TAVR Transaortic Approach IMPACT ON PROVIDER TF vs. Alternative Access: Fluoroscopy time with TF (20±7 v. 11±3 min, p<0.001) Radiation exposure with AA (15.1 v. 5.5 mrads, p<0.001) Radiation exposure for TF cases in hybrid room (9.0 v. 2.2 mrads, p<0.001) Rad Pads did not decrease exposure (9.4 v. 9.0 mrads, p=0.82) Team Radiation Exposures for TAVR AA -Hybrid OR TF-Hybrid OR TF-Cath Lab Wash U. Submitted to AATS 2016
29 CONCLUSIONS Transfemoral and alternative access approaches remain complementary approaches and have their unique advantages and disadvantages A transfemoral-first strategy has been adopted at most institutions and TF implantation remains the most commonly used approach around the world
30 CONCLUSIONS Transaortic procedures will play an increasing role in the future and overcome some of the problems associated with TA insertion TAVR physicians need to be familiar with all approaches and should tailor the implant strategy to the particular patient
31 Thank you for your attention.
CIPG Transcatheter Aortic Valve Replacement- When Is Less, More?
CIPG 2013 Transcatheter Aortic Valve Replacement- When Is Less, More? James D. Rossen, M.D. Professor of Medicine and Neurosurgery Director, Cardiac Catheterization Laboratory and Interventional Cardiology
More informationTranscatheter Aortic Valve Replacement TAVR
Transcatheter Aortic Valve Replacement TAVR Paul Gordon, MD Associate Prof of Medicine, Brown University Director, Cardiac Catheterization Laboratory The Miriam Hospital Disclosures: none 100 Symptomatic
More informationIncorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI)
Incorporating the intermediate risk in Transcatheter Aortic Valve Implantation (TAVI) Larry S. Dean, MD, MSCAI Past President SCAI Professor of Medicine and Surgery University of Washington School of Medicine
More informationTranscatheter Valve Replacement: Current State in 2017
Transcatheter Valve Replacement: Current State in 2017 Marc A. Sintek MD Assistant Professor of Medicine Interventional Cardiology Cardiovascular Division Washington University in St. Louis Missouri ACP
More informationTAVI After PARTNER-2 : The Hamilton Approach
TAVI After PARTNER-2 : The Hamilton Approach James L. Velianou MD FRCPC Interventional Cardiology Hamilton General Hospital St Catharines General Hospital Associate Professor of Medicine McMaster University
More informationMinimalist Transcatheter Aortic Valve Replacement (MA-TAVR)
Minimalist Transcatheter Aortic Valve Replacement (MA-TAVR) Jensen HA, Condado JF, Devireddy C, Binongo JN, Leshnower BG, Babaliaros V, Sarin EL, Lerakis S, Guyton RA, Stewart JP, Syed AQ, Mavromatis K,
More informationAfter PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients?
After PARTNER 2A/S3i and SURTAVI: What is the Role of Surgery in Intermediate-Risk AS Patients? Vinod H. Thourani, MD Professor of Surgery and Medicine Emory University Disclosure Statement of Financial
More informationTranscatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data
Transcatheter Aortic Valve Replacement: Current and Future Devices: How do They Work, Eligibility, Review of Data Echo Florida 2013 Jonathan J. Passeri, M.D. Co-Director, Heart Valve Program Director,
More informationAortic Valve Stenosis and TAVR: Putting it all together.
Aortic Valve Stenosis and TAVR: Putting it all together. Maria L. Held, MSN CNS Valve Clinic Coordinator at The Cleveland Clinic Alliance of Cardiovascular Professionals April 14 th, 2018 Brief Anatomy
More informationTAVI Summit Eberhard Grube MD FACC, FSCAI Universitätsklinik Bonn, Medizinische Klinik und Poliklinik II, Bonn, Germany
TAVI Summit 2012 Seoul, September 8, 2012 TAVI Various Access Sites Eberhard Grube MD FACC, FSCAI Universitätsklinik Bonn, Medizinische Klinik und Poliklinik II, Bonn, Germany StanfordUniversity University,
More informationPolicy Specific Section: March 30, 2012 March 7, 2013
Medical Policy Transcatheter Aortic Valve Replacement for Aortic Stenosis Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Surgery Original Policy Date: Effective Date:
More informationTAVR Update: Open vs. Closed Future Directions
TAVR Update: Open vs. Closed Future Directions Michael J. Reardon, M.D. Professor of Cardiothoracic Surgery Methodist DeBakey Heart & Vascular Center Disclosures Advisory Board Medtronic Consultant Medtronic
More information2/15/2018 DISCLOSURES OBJECTIVES. Consultant for BioSense Webster, a J&J Co. Aortic stenosis background. Short history of TAVR
TRANSCATHETER AORTIC VALVE REPLACEMENT IN 2018: IS IT NOW THE STANDARD OF CARE? 22 ND ANNUAL COASTAL CARDIAC & VASCULAR CONFERENCE FEBRUARY 17, 2018 R. David Anderson, MD, MS, FACC, FSCAI Professor of
More informationAortic Stenosis: Open vs TAVR vs Nothing
Aortic Stenosis: Open vs TAVR vs Nothing Wilson Y. Szeto, MD Associate Professor of Surgery Surgical Director, Transcatheter Cardio-Aortic Therapies Associate Director, Thoracic Aortic Surgery Division
More informationAortic Stenosis: Background
Transcatheter Aortic Valve Replacement in Low Surgical Risk Patients Barry George, MD The Ohio State University Structural Heart Disease Course May 19 th, 2017 Aortic Stenosis: Background Severe Symptomatic
More informationIgor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of Medicine Harvard Medical School
Aortic Stenosis: Current State of Percutaneous Therapies, Emerging Technologies and Future Directions Igor Palacios, MD Director of Interventional Cardiology Massachusetts General Hospital Professor of
More informationEdwards Sapien. Medtronic CoreValve. Inoperable FDA approved High risk: in trials. FDA approved
Transcatheter Aortic Valve Replacement Symptomatic Aortic Stenosis Asymptomatic Juan Crestanello, MD Interim Director, Division of Cardiac Surgery Associate Professor Division of Cardiac Surgery The Ohio
More informationPrince Sultan Cardiac Center Experience Riyadh, Saudi Arabia
Transcatheter Transapical Aortic Valve Implantation Prince Sultan Cardiac Center Experience Riyadh, Saudi Arabia Ahmed Elwatidy, MD,PhD, FRCS S Kassab, MD,S Ahmari, MD, H Amri, MD, H Ismail, MD, A Calafiori,
More informationEvolving and Expanding Indications for TAVR
Evolving and Expanding Indications for TAVR Wilson Y. Szeto, MD Associate Professor of Surgery Surgical Director, Transcatheter Cardio-Aortic Therapies Associate Director, Thoracic Aortic Surgery Division
More information2/28/2010. Speakers s name: Paul Chiam. I have the following potential conflicts of interest to report: NONE. Antegrade transvenous transseptal route
Transcatheter Aortic Valve Implantation Asian perspective Speakers s name: Paul Chiam Paul TL Chiam MBBS, MRCP, FACC I have the following potential conflicts of interest to report: NONE Consultant National
More informationTAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
More informationAortic valve implantation using the femoral and apical access: a single center experience.
Aortic valve implantation using the femoral and apical access: a single center experience. R. Hoffmann, K. Brehmer, R. Koos, R. Autschbach, N. Marx, G. Dohmen Rainer Hoffmann, University Aachen, Germany
More informationDr. Jean-Claude Laborde
Medtronic CoreValve Experience Alternative Access (Subclavian) and Technology Evolution of the Medtronic CoreValve TAVI System Dr. Jean-Claude Laborde Glenfield Hospital, Leicester, U.K. St George Hospital,
More informationEstablishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS
Establishing the New Standard of Care for Inoperable Aortic Stenosis THE PARTNER TRIAL COHORT B RESULTS E D W A R D S T R A N S C A T H E T E R H E A R T V A L V E P R O G R A M T H E P A R T N E R T R
More informationAortic Stenosis Background and Breakthroughs in Treatment: TAVR Update
Aortic Stenosis Background and Breakthroughs in Treatment: TAVR Update Howard J Broder MD Interventional Cardiology DaVita Medical Group/ Healthcare Partners Cardiology Disclosures for Howard J Broder
More informationAortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC
Aortic Stenosis and TAVR TARUN NAGRANI, MD INTERVENTIONAL AND ENDOVASCULAR CARDIOLOGIST, SOMC No Financial Disclosures Aortic Stenosis AS is an insidious disease with a long latency period followed by
More informationValvular Intervention
Valvular Intervention Outline Introduction Aortic Stenosis Mitral Regurgitation Conclusion Calcific Aortic Stenosis Deformed Eccentric Calcified Nodular Rigid HOSTILE TARGET difficult to displace prone
More informationAlternate Vascular Access for TAVR. Gian Paolo Ussia Campus Bio-medico University, Rome Italy
Alternate Vascular Access for TAVR Gian Paolo Ussia Campus Bio-medico University, Rome Italy g.ussia@unicampus.it REQUIRED Gian Paolo Ussia I have no relevant financial relationships Transcatheter Valves
More informationAn Update on the Edwards TAVR Results. Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St.
An Update on the Edwards TAVR Results Zvonimir Krajcer, MD Director, Peripheral Intervention Texas Heart Institute at St. Luke s Hospital Disclosures On the speaker s bureau for Endologix, TriVascular,
More informationAortic Valve Practice Guidelines: What Has Changed and What You Need to Know
Aortic Valve Practice Guidelines: What Has Changed and What You Need to Know James F. Burke, MD Program Director Cardiovascular Disease Fellowship Lankenau Medical Center Disclosure Dr. Burke has no conflicts
More informationAustralia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes
Australia and New Zealand Source Registry Edwards Sapien Aortic Valve 30 day Outcomes A/ Professor Darren Walters On behalf of the ANZ Source Investigators Director of Cardiology Brisbane, Australia ANZ
More informationA new option for the Diagnosis and Management of Valvular Heart Disease. Oregon Comprehensive Valve Center
A new option for the Diagnosis and Management of Valvular Heart Disease Oregon Comprehensive Valve Center I have no disclosures Oregon Comprehensive Valve Center Weekly multidisciplinary case conferences
More informationThe Role of TAVI in high-risk and normal-risk Patients
The Role of TAVI in high-risk and normal-risk Patients Joachim Schofer Hamburg University Cardiovascular Center and Department for percutaneous treatment of structural heart disease Albertinen Heart Center
More informationValve Disease. Valve Surgery. Total Volume. In 2016, Cleveland Clinic surgeons performed 3039 valve surgeries.
Valve Surgery Total Volume 1 1 Volume 35 3 5 15 1 5 1 13 1 N = 773 5 79 15 93 1 339 In 1, surgeons performed 339 valve surgeries. surgeons have implanted more than 1, bioprosthetic aortic valves since
More informationLOW RISK TAVR. WHAT THE FUTURE HOLDS
LOW RISK TAVR. WHAT THE FUTURE HOLDS Michael J. Reardon, M.D. Professor of Cardiothoracic Surgery Allison Family Distinguish Chair of Cardiovascular Research Houston Methodist DeBakey Heart & Vascular
More informationHeart Team For TAVI Who and How?
2 nd TAVI Summit 2012, Seoul Corea Heart Team For TAVI Who and How? Alain Cribier, MD, Charles Nicolle Hospital University of Rouen, France Disclosure Edwards Lifesciences Consultant Training / proctoring
More informationPercutaneous Valve in Native With and Without Mitral Valve Calcification: When To Go Hybrid
Percutaneous Valve in Native With and Without Mitral Valve Calcification: When To Go Hybrid Deborah Tabachnick, MD Cardiac Surgeon The Heart Hospital Baylor Plano Baylor Scott & White Health Disclosures
More informationResults of Transapical Valves. A.P. Kappetein Dept Cardio-thoracic surgery
Results of Transapical Valves A.P. Kappetein Dept Cardio-thoracic surgery Rotterda am, The Netherlands 2002 FIM 2003 2005 2006 2010 THV THV Cribier-Edwards Edwards Edwards Sapien Sapien XT Bovine pericardium
More informationDebate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI
Debate: SAVR for Low-Risk Patients in 2017 is Obsolete AVR vs TAVI Joseph E. Bavaria, MD Roberts-Measey Professor of Surgery Vice Chair, Division of Cardiovascular Surgery University of Pennsylvania Immediate
More informationTranscatheter Aortic Valve Implantation. SSVQ November 23, 2012 Centre Mont-Royal 15:40
Transcatheter Aortic Valve Implantation SSVQ November 23, 2012 Centre Mont-Royal 15:40 Nicolo Piazza MD, PhD, FRCPC, FESC, FACC McGill University Health Center German Heart Center Munich 1 First-in-Human
More informationTranscatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients:
Transcatheter Aortic Valve Replacement with a Self-Expanding Prosthesis or Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 1-Year Results from the SURTAVI Clinical Trial Nicolas M. Van
More informationMaurizio D Amico M.D.
TAVI BEST CANDIDATE AND OPTIMIZED LONG TERM FOLLOW-UP Maurizio D Amico M.D. Dipartimento Cardiovascolare e Toracico Città della Salute e della Scienza, Turin Italy Regional Guidelines for TAVI implantation
More informationTAVR for low-risk patients in 2017: not so fast.
TAVR for low-risk patients in 2017: not so fast. Enrico Ferrari, MD, FETCS Cardiac Surgery Department Cardiocentro Ticino Foundation Lugano, Switzerland Conflicts of Interest Consultant and proctor for
More informationTAVR IN INTERMEDIATE-RISK PATIENTS
TAVR IN INTERMEDIATE-RISK PATIENTS K. Lampropoulos MD, PhD, FESC, MEAPCI Interventional Cardiologist Evangelismos General Hospital The Burden of Valve Disease Prevalence Survival NATURAL HISTORY OF AS
More informationLe TAVI pour tout le monde?
Le TAVI pour tout le monde? Thierry Lefèvre Institut Cardiovasculaire Paris Sud, Massy Disclosure Statement of Financial Interest I currently have, or have had over the last two years, an affiliation or
More informationTAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy
TAVR today: High Risk, Intermediate Risk Population, and Valve in Valve Therapy Alan Zajarias, MD FACC Structural Interventional Fellowship Director Associate Professor Medicine Cardiovascular Division
More informationNew Cardiovascular Devices and Interventions: Non-Contrast MRI for TAVR Abhishek Chaturvedi Assistant Professor. Cardiothoracic Radiology
New Cardiovascular Devices and Interventions: Non-Contrast MRI for TAVR Abhishek Chaturvedi Assistant Professor Cardiothoracic Radiology Disclosure I have no disclosure pertinent to this presentation.
More informationTAVR SPRING 2017 The evolution of TAVR
TAVR SPRING 2017 The evolution of TAVR Matthew Johnson, MD Disclosers None Evolution of the Balloon- Expandable Transcatheter Valves Cribier 2002 SAPIEN 2006 SAPIEN XT 2009 SAPIEN 3 2013 * Sheath compatibility
More informationPotential conflicts of interest
Potential conflicts of interest Speaker's name: Petros Dardas MEDTRONIC proctor for TAVI Intermediate risk 83 FEMALE COAD SEVERE AS NYHA III Mean gradient 35 mmhg, AVA 0.45cm2, SVI 21ml/m2 Paradoxical
More informationMasterclass III Advances in cardiac intervention. Percutaneous valvular intervention a novel approach
Masterclass III Advances in cardiac intervention Percutaneous valvular intervention a novel approach Professor Roger Boyle CBE National Director for Heart Disease and Stroke London Medical therapy Medical
More informationValve Disease. Valve Surgery. In 2015, Cleveland Clinic surgeons performed 2943 valve surgeries.
Valve Surgery 11 15 Volume 3 1 11 1 13 1 N = 1 773 5 79 15 93 In 15, surgeons performed 93 valve surgeries. surgeons have implanted more than 1,5 bioprosthetic aortic valves since the 199s, with excellent
More informationIn Process, Unpublished STS/ACC TVT Registry Manuscripts
In Process, Unpublished STS/ACC TVT Registry Manuscripts The following pages list current research and publications proposals that have been recently approved, are under analysis, are under manuscript
More informationTranscatheter Aortic Valve Replacement (TAVR)
UW MEDICINE PATIENT EDUCATION Transcatheter Aortic Valve Replacement (TAVR) Treatment for aortic stenosis This handout explains when your doctor may advise TAVR to treat aortic stenosis. It includes the
More informationTAVR Samir Kapadia, MD Professor of Medicine Director, Cardiac Catheterization Laboratory. Cleveland Clinic.
TAVR 2015 Samir Kapadia, MD Professor of Medicine Director, Cardiac Catheterization Laboratory Outline Aortic Stenosis TAVR Who should be considered for TAVR What are the treatment options? Valves, Approaches
More informationAortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV?
Aortic Stenosis: Interventional Choice for a 70-year old- SAVR, TAVR or BAV? Interventional Choice for a 90-year old- SAVR, TAVR or BAV? Samin K Sharma, MD, FACC, FSCAI Director Clinical & Interventional
More informationProf. Dr. Thomas Walther. TAVI in ascending aorta / aortic root dilatation
Prof. Dr. Thomas Walther TAVI in ascending aorta / aortic root dilatation nn AorticStenosis - Guidelines TAVI and aortic aneurysm? Few data published. EJCTS 2014;46:228-33 TAVI and aortic aneurysm? Few
More informationHardware in the Chest - From VADs to Valves
Hardware in the Chest - From VADs to Valves Cristina Fuss, MD Purpose Recognize the device Indication and function Cristina Fuss, MD Department of Diagnostic Radiology FROM VADS TO VALVES Implanting technique
More informationFive-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial
Five-Year Outcomes of Transcatheter Aortic Valve Replacement (TAVR) in Inoperable Patients With Severe Aortic Stenosis: The PARTNER Trial Samir R. Kapadia, MD On behalf of The PARTNER Trial Investigators
More informationIs TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients
Is TAVR Now Indicated in Even Low Risk Aortic Valve Disease Patients Saibal Kar, MD, FACC, FAHA, FSCAI Director of Interventional Cardiac Research Cedars Sinai Heart Institute, Los Angeles, CA Potential
More informationStructural Heart Disease Transcatheter Aortic Valve Replacement (TAVR)
Structural Heart Disease Transcatheter Aortic Valve Replacement (TAVR) Kathleen Harper DO FACC FACP 87 Chief, Cardiology Section VA Maine Healthcare Kathleen.Harper@va.gov Prevalence of Aortic Stenosis
More informationTrend and Outcomes of Direct Transcatheter Aortic Valve Replacement from a Single-Center Experience
Cardiol Ther (2018) 7:191 196 https://doi.org/10.1007/s40119-018-0115-0 BRIEF REPORT Trend and Outcomes of Direct Transcatheter Aortic Valve Replacement from a Single-Center Experience Anthony A. Bavry.
More informationEmbolic Protection Devices for Transcatheter Aortic Valve Replacement
Embolic Protection Devices for Transcatheter Aortic Valve Replacement James M. McCabe, MD Medical Director, Cardiac Cath Lab University of Washington Seattle, WA Disclosures Proctoring and honoraria for
More informationBioprosthetic Mitral Valve Dysfunction: Innovation and Evolution of a New Therapeutic Technique
Bioprosthetic Mitral Valve Dysfunction: Innovation and Evolution of a New Therapeutic Technique Charanjit S. Rihal MD MBA Professor and Chair Division of Cardiovascular Diseases Mayo Clinic DISCLOSURES
More informationThe Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health. Adam J. Saltzman, MD Cardiovascular Care Center
The Transcatheter Aortic Valve Replacement (TAVR)Program at Southcoast Health Adam J. Saltzman, MD Cardiovascular Care Center Southcoast Health Disclosures Edwards Lifesciences: speaking honorarium Outline
More informationPreprocedural evaluation for TAVR
KEBE 30/05/15 Preprocedural evaluation for TAVR Ioannis Iakovou, MD, PhD Interventional Cardiology Onassis Cardiac Surgery Center Athens, Greece Clinical Pathway: Developing Peri- Procedural Protocols
More informationIntegrating Innovative Technologies into the Care of Cardiac Patients
Integrating Innovative Technologies into the Care of Cardiac Patients Marc J. Semigran MD Medical Director, Heart Failure & Cardiac Transplantation MGH Associate Professor Harvard Medical School Presenter
More informationDisclosures 4/16/2018. What s New in Valvularand Structural Heart Disease. None relevant to the presentation
What s New in Valvularand Structural Heart Disease Ryan C. Shelstad, MD Surgical Enthusiast, Valvular and Structural Heart Disease Bryan Heart Cardiothoracic Surgery Disclosures None relevant to the presentation
More informationPost-TAVI Cerebral Embolisms and Potential Protection Means
Post-TAVI Cerebral Embolisms and Potential Protection Means Josep Rodés-Cabau, MD Quebec Heart & Lung Institute, Laval University Quebec City, Quebec, Canada EBR Marseille, May 2012 Conflict of Interest
More informationAPOLLO TMVR Trial Update: Case Presentation
APOLLO TMVR Trial Update: Case Presentation Anelechi Anyanwu, MD, MSc, FRCS-CTh Professor and Vice-Chairman Department of Cardiovascular Surgery Icahn School of Medicine at Mount Sinai New York, NY Disclosure
More informationTAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant
More informationSeverity of AS Degree of AV calcification (? Bicuspid AV), annulus size, & aortic root
The role of Cardiac Imaging modalities in evaluation & selection of patients for Trans-catheter Aortic Valve Implantation Dr.Saeed AL Ahmari Consultant Cardiologist Prince Sultan Cardaic Center, Riyadh
More informationTAVR in 2020: What is Next!!!!
TAVR in 2020: What is Next!!!! Vinod H. Thourani, MD Professor of Surgery Chairman, Department of Cardiac Surgery Medstar Heart and Vascular Institute Washington Hospital Center Washington, DC Disclosures
More informationSurgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea
Surgical AVR: Are there any contraindications? Pyowon Park Samsung Medical Center Seoul, Korea Contents Decision making in surgical AVR in old age Clinical results of AVR with tissue valve Impact of 19mm
More informationTAVR in patients with. End-Stage CKD or in Renal Replacement Therapy:
TAVR in patients with End-Stage CKD or in Renal Replacement Therapy: Special Considerations and Prevention of early Valve Failure Antonios Chalapas, MD, PhD, FESC THV & Hygeia Hospital Heart Team Athens,
More informationTAVR in Intermediate Risk Populations /Optimizing Systems for TAVR
TAVR in Intermediate Risk Populations /Optimizing Systems for TAVR Saibal Kar, MD, FACC, FAHA, FSCAI Professor of Medicine Director of Interventional Cardiac Research Smidt Heart Institute, Cedars-Sinai
More informationTranscatheter aortic valve replacement is considered investigational for all other indications.
Medical Policy Original Policy Date: March 30, 2012 Effective Date: July 1, 2018 Section: 7.0 Surgery Page: Page 1 of 33 Policy Statement Transcatheter aortic valve replacement with an U.S. Food and Drug
More informationPeri-operative results and complications in 15,964 transcatheter aortic valve implantations from the German Aortic valve RegistrY (GARY)
Peri-operative results and complications in 15,964 transcatheter aortic valve implantations from the German Aortic valve RegistrY (GARY) Thomas Walther, Christian W. Hamm, Gerhard Schuler, Alexander Berkowitsch,
More information> 1200 Patients
> 1200 Patients 2002-2008 2008 Transfemoral (n=628) Transapical (n=457) Antegrade N=59 Retrograde N=569 TRAVERCE n=172 RECAST n = 24 REVIVE II n = 106 REVIVAL II n =40 Early First in Man irevive n = 22
More informationProsthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis
Prosthesis-Patient Mismatch in High Risk Patients with Severe Aortic Stenosis in a Randomized Trial of a Self-Expanding Prosthesis George L. Zorn, III On Behalf of the CoreValve US Clinical Investigators
More informationIndication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
More informationVascular complications of embolized core valve
Vascular complications of embolized core valve Suhail Dohad, MD FACC Director of Endovascular services, Interventional Cardiology Cardiovascular Research Foundation of Southern California, CVMG Director
More informationAortic Stenosis Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan
Aortic Stenosis - 2011 Steven F. Bolling, M.D. Professor of Cardiac Surgery University of Michigan Aortic Surgery Aortic Stenosis EB CT - Ca++ everywhere! Surgery for Aortic Stenosis 100,000 USA + 100,000
More informationTranscatheter Aortic Valve Implantation Present Status and Perspectives
Transcatheter Aortic Valve Implantation Present Status and Perspectives Angioplasty Summit TCTAP 2010 Alain Cribier, MD University of Rouen, France Transcatheter Aortic Valve Implantation has entered the
More informationTranscatheter Valve Therapies Update
Providence Heart and Vascular Institute Transcatheter Valve Therapies Update Where In The H*@# Is All This Going??? Robert Hodson MD Medical Director, Providence Valve Center October 24, 2015 DISCLOSURES
More informationTRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH
TRANSCATHETER AORTIC VALVE IMPLANTATION: PSCC EXPERIENCE DR HUSSEIN ALAMRI PSCC RIYADH Available systems: Edwards (TA and TF) and Core valve. INTRODUCTION 3 4% 0f > 65 y. 30 40% of elderly denied surgery,.
More informationEdwards Transcatheter AVR: Have the Outcomes Changed after CE Approval?
Edwards Transcatheter AVR: Have the Outcomes Changed after CE Approval? Update from PARTNER EU and SOURCE Registries T. Lefèvre Disclosure Statement Cardiologist Interventional cardiologist 1 st PABV in
More informationEssential Support for a Structural Heart Program: The Valve and Structural Heart Clinic
Essential Support for a Structural Heart Program: The Valve and Structural Heart Clinic Vincent Varghese, DO, FACC, FSCAI Director, Interventional Cardiology Fellowship Program Deborah Heart and Lung Center
More informationPreoperative Anemia versus Blood Transfusion: Which is the Culprit for Worse Outcomes in Cardiac Surgery?
Preoperative Anemia versus Blood Transfusion: Which is the Culprit for Worse Outcomes in Cardiac Surgery? Damien J. LaPar MD, MSc, James M. Isbell MD, MSCI, Jeffrey B. Rich MD, Alan M. Speir MD, Mohammed
More informationValvular Heart Disease and Adult Congenital Intervention. A Pichard, MD. Director Cath Labs, Washington Hospital Center. Georgetown University.
Valvular Heart Disease and Adult Congenital Intervention. A Pichard, MD Director Cath Labs, Washington Hospital Center. ProfessorofMedicine (Cardiology), Georgetown University. Conflict of Interest Proctor
More informationTAVR for Valve-In-Valve. Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology
TAVR for Valve-In-Valve Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology Temple Hearth and Vascular Institute Disclosures: Consultant: Cardiac Assist TAVR for
More informationDevelopments in Valve Surgery
Developments in Valve Surgery Introduction Will discuss Aortic Valve and Mitral Valve surgery What is a mini valve operation? When do we do traditional valve surgery (SAVR, SMVR) vs. mini valve surgery
More informationPlanning for Transcatheter Aortic Valve Replacement
WHAT WOULD YOU DO? Planning for Transcatheter Aortic Valve Replacement MODERATOR: MAURICIO G. COHEN, MD, FACC, FSCAI PANEL: SANTIAGO GARCIA, MD, FACC, FSCAI; WILLIAM O NEILL, MD; AND MOLLY SZERLIP, MD,
More informationVALVULOPATIE: NUOVE SOLUZIONI.
VALVULOPATIE: NUOVE SOLUZIONI www.fisiokinesiterapia.biz Nkomo, Lancet 2006 ELDERLY POPULATION PROJECTION IN USA 65-84 Years Old 85 and Older 77,2 Millions of people 34,8 4,3 30,5 53,8 6,8 47 14,3 62,9
More informationTAVI: Nouveaux Horizons
TAVI: Nouveaux Horizons EUAPI580i 432HQ14NP02353 Institut de Cardiologie de la Pitié-Salpêtrière jean-philippe.collet@psl.aphp.fr www.action-coeur.org Objectifs Les recommandations Le TAVI en chiffre La
More informationValvular Heart Disease:
Oklahoma Heart Institute 1120 South Utica Avenue Tulsa, OK 74104 Valvular Heart Disease: Transcatheter AorticValve Replacement (TAVR) Transcatheter Mitral Valve Repair (TMVR) Oklahoma Heart Institute Physicians
More informationHOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY?
HOW IMPORTANT ARE THESE ECHO MEASUREMENTS ANYWAY? John D. Carroll, MD Professor, Director of Interventional Cardiology and Co-Medical Director of the Cardiac and Vascular Center, University of Colorado
More informationIn Process, Unpublished STS/ACC TVT Registry Manuscripts
In Process, Unpublished STS/ACC TVT Registry Manuscripts The following pages list current research and publications proposals that have been recently approved, are under analysis, are under manuscript
More information1-YEAR OUTCOMES FROM JOHN WEBB, MD
1-YEAR OUTCOMES FROM JOHN WEBB, MD ON BEHALF OF THE SAPIEN 3 INVESTIGATORS UNIVERSITY OF BRITISH COLUMBIA VANCOUVER, CANADA Potential conflicts of interest Speaker's name: John Webb I have the following
More informationTissue vs Mechanical What s the Data??
Biological (Tissue) Valve in a 60 year old patient: Debate Tissue vs Mechanical What s the Data?? Joseph E. Bavaria, MD Immediate-Past President - Society of Thoracic Surgeons (STS) Brooke Roberts-William
More informationTAVR y Enfermedad Coronaria. Mauricio G. Cohen, MD, FACC, FSCAI Director, Cardiac Catheterization Lab Associate Professor of Medicine
TAVR y Enfermedad Coronaria Mauricio G. Cohen, MD, FACC, FSCAI Director, Cardiac Catheterization Lab Associate Professor of Medicine CAD and AS Similar Pathological Processes CAD in TAVR Patients (n=390)
More information